Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H10O8 |
| Molecular Weight | 210.1388 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O
InChI
InChIKey=DSLZVSRJTYRBFB-LLEIAEIESA-N
InChI=1S/C6H10O8/c7-1(3(9)5(11)12)2(8)4(10)6(13)14/h1-4,7-10H,(H,11,12)(H,13,14)/t1-,2-,3-,4+/m0/s1
| Molecular Formula | C6H10O8 |
| Molecular Weight | 210.1388 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Glucaric acid is a non-toxic, naturally occurring compound, which is found in small amounts in plants and mammals, including humans. Salts of glucaric acid have potent antiproliferative properties in vivo. The risk of cancer development can be reduced by ingesting food rich in glucaric acid or self-medication with its salts. Glucaric acid inhibits bacterial beta-glucuronidase, thus increasing the excretion of conjugated xenobiotic compounds and decreasing activity of harmful substances. Inhibition of beta-glucuronidase ultimately results in potentially decreasing the risk of carcinogenesis. Calcium salt of the acid demonstrated anti-cancer activity in patients with breast cancer (phase I clinical trial) and in preclinical models of liver, lung, colon and skin cancers. Calcium-D-glucarate is being marketed as a dietary supplement.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Gut microflora beta-glucuronidase |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
11 umol/kg single, topical Studied dose Dose: 11 umol/kg Route: topical Route: single Dose: 11 umol/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
27.5 umol/kg single, topical Studied dose Dose: 27.5 umol/kg Route: topical Route: single Dose: 27.5 umol/kg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mild reductions in mitochondrial NAD-dependent isocitrate dehydrogenase activity result in altered nitrate assimilation and pigmentation but do not impact growth. | 2010-01 |
|
| Symbiosis between microorganisms from kombucha and kefir: Potential significance to the enhancement of kombucha function. | 2010-01 |
|
| Convenient large-scale synthesis of D-glucaro-1,4:6,3-dilactone. | 2009-11-06 |
|
| Enzymatic assay of D-glucuronate using uronate dehydrogenase. | 2009-09-15 |
|
| Micro-PET imaging of beta-glucuronidase activity by the hydrophobic conversion of a glucuronide probe. | 2009-09 |
|
| Global effect of RpoS on gene expression in pathogenic Escherichia coli O157:H7 strain EDL933. | 2009-08-03 |
|
| Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). | 2009-07-28 |
|
| Characterization of metabolites of sibutramine in primary cultures of rat hepatocytes by liquid chromatography-ion trap mass spectrometry. | 2009-02 |
|
| Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. | 2009-01-08 |
|
| Metabolic characterization of loci affecting sensory attributes in tomato allows an assessment of the influence of the levels of primary metabolites and volatile organic contents. | 2009 |
|
| Decreased valproate level caused by VPA-glucuronidase inhibition by carbapenem antibiotics. | 2008-12 |
|
| Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection. | 2008-11-01 |
|
| Chiral separation of amino acids and glycyl dipeptides by chiral ligand-exchange capillary electrophoresis comparing Cu(II), Co(II), Ni(II) and Zn(II) complexes of three different sugar acids. | 2008-09-19 |
|
| [The biological role of D-glucaric acid and its derivatives: potential use in medicine]. | 2008-09-05 |
|
| Protective effects of D-glucaro-1,4-lactone against oxidative modifications in blood platelets. | 2008-07 |
|
| New insights into the alternative D-glucarate degradation pathway. | 2008-06-06 |
|
| Development of a method for the quantification of D-glucaric acid in different varieties of grapefruits by high-performance liquid chromatography and mass spectra. | 2008-05-09 |
|
| Attitude of physicians towards iron supplementation in hemodialysis patients treated with erythropoietin. | 2008-01-23 |
|
| Intravenous Iron Saccharate Complex: Guidelines for its use in the Management of Anemia of Renal Disease. | 2008-01-23 |
|
| Pregnancy in dialysis patients: a case series. | 2008-01-20 |
|
| Beneficial effects of maintenance intravenous iron saccharate in hemodialysis patients. | 2008-01-19 |
|
| [Improvement of urinary d-glucaric acid assay and its application]. | 2008-01 |
|
| Diversity of Shewanella population in fish Sparus aurata harvested in the Aegean Sea. | 2007-09 |
|
| GntR family of regulators in Mycobacterium smegmatis: a sequence and structure based characterization. | 2007-08-23 |
|
| Evolution of enzymatic activities in the enolase superfamily: L-talarate/galactarate dehydratase from Salmonella typhimurium LT2. | 2007-08-21 |
|
| Effect of intravenous iron saccharate on the requirements of erythropoietin in hemodialysis patients. | 2007-07-31 |
|
| CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. | 2007-07 |
|
| Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. | 2007-05 |
|
| The taxonomy of Enterobacter sakazakii: proposal of a new genus Cronobacter gen. nov. and descriptions of Cronobacter sakazakii comb. nov. Cronobacter sakazakii subsp. sakazakii, comb. nov., Cronobacter sakazakii subsp. malonaticus subsp. nov., Cronobacter turicensis sp. nov., Cronobacter muytjensii sp. nov., Cronobacter dublinensis sp. nov. and Cronobacter genomospecies 1. | 2007-04-17 |
|
| [Current recommendations for the treatment of iron deficiency anemia]. | 2007-04-04 |
|
| Iron therapy for renal anemia: how much needed, how much harmful? | 2007-04 |
|
| alpha-ketoglutaric semialdehyde dehydrogenase isozymes involved in metabolic pathways of D-glucarate, D-galactarate, and hydroxy-L-proline. Molecular and metabolic convergent evolution. | 2007-03-02 |
|
| Regulation of the kduID operon of Bacillus subtilis by the KdgR repressor and the ccpA gene: identification of two KdgR-binding sites within the kdgR-kduI intergenic region. | 2007-03 |
|
| Poly(glycoamidoamine)s for gene delivery. structural effects on cellular internalization, buffering capacity, and gene expression. | 2007-01-18 |
|
| Induction of apoptosis by calcium D-glucarate in 7,12-dimethyl benz [a] anthracene-exposed mouse skin. | 2007 |
|
| Esterification of select polyols with D-glucaric acid as model reactions for esterification of starch. | 2006-11-27 |
|
| Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. | 2006-11 |
|
| Acute injury with intravenous iron and concerns regarding long-term safety. | 2006-09 |
|
| Tetranuclear copper(II) complexes bridged by alpha-D-glucose-1-phosphate and incorporation of sugar acids through the Cu4 core structural changes. | 2006-08-21 |
|
| [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia]. | 2006-01-31 |
|
| Poly(glycoamidoamine)s for gene delivery: stability of polyplexes and efficacy with cardiomyoblast cells. | 2006-01-19 |
|
| A gold standard set of mechanistically diverse enzyme superfamilies. | 2006 |
|
| Effect of antiepileptic drugs on the urinary excretion of porphyrins in non-porphyric subjects. | 2005-12 |
|
| Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. | 2005-10-05 |
|
| Purification and characterization of a beta-glucuronidase present during embryogenesis of the mollusk Pomacea sp. | 2005-10 |
|
| Biomarker measurements in a coastal fish-eating population environmentally exposed to organochlorines. | 2005-10 |
|
| Induction of endogenous pathways by antiepileptics and clinical implications. | 2005-10 |
|
| [Post-haemodilution anaemia in paediatric cardiac surgery: benefit of intravenous iron therapy]. | 2005-10 |
|
| Crystal structure and aqueous solubility of ammonium D-glucarate. | 2005-09-26 |
|
| Iron management in hemodialysis patients: optimizing outcomes in Vicenza, Italy. | 2003-06-01 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:21:42 GMT 2025
by
admin
on
Mon Mar 31 19:21:42 GMT 2025
|
| Record UNII |
QLZ991V4A2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
35392
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
17301
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
QLZ991V4A2
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
201-768-1
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
DTXSID60859455
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
33801
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
D005937
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
1788997
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
SACCHARIC ACID
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
m5755
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | Merck Index | ||
|
33037
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
16002
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
87-73-0
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY | |||
|
DB03603
Created by
admin on Mon Mar 31 19:21:42 GMT 2025 , Edited by admin on Mon Mar 31 19:21:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
